TEDA Unveils Plan For Biopharmaceutical Industry
This article was originally published in PharmAsia News
Executive Summary
The Tianjin Economic-Technological Development Area recently unveiled its plans for the biopharmaceutical industry. By 2015, it aims to establish a biopharmaceutical industry worth RMB 50 billion, attracting more than 40 large manufacturing enterprises and targeting export rates of 30 percent. TEDA seeks to be an important Asia-Pacific pharmaceutical R&D and manufacturing hub with links to international contract research and manufacturing organizations. A biopharmaceutical industry cluster will be set up to integrate pharmaceutical MNCs, local leading companies and small- and medium-sized innovative enterprises. TEDA aims to develop its own unique characteristics in the CRO, CMO and medical device domains, nurture a core batch of leading pioneers for Tianjin's biopharmaceutical industry and make breakthroughs in new drug creation. (Click here for more - Chinese Language)